表纸
市场调查报告书

丛发性头痛:开发中产品分析

Cluster Headache Syndrome (Cluster Headache) - Pipeline Review, H1 2019

出版商 Global Markets Direct 商品编码 465225
出版日期 内容资讯 英文 58 Pages
订单完成后即时交付
价格
Back to Top
丛发性头痛:开发中产品分析 Cluster Headache Syndrome (Cluster Headache) - Pipeline Review, H1 2019
出版日期: 2019年01月31日内容资讯: 英文 58 Pages
简介

丛发性头痛是沿著头部一侧发生的疼痛。经常发生在眼睛的周围,后面或上方。症状包括灼热,尖锐,稳定的疼痛,红眼,流鼻涕,泪水过多和脸红。风险因素包括年龄和性别。治疗包括抗炎(类固醇)药物和triptan类。

本报告提供丛发性头痛的治疗药开发平台现状及最新更新的各开发阶段比较分析,提供您涵括最新的新闻和发表之企业和研究机关开发中治疗药,治疗药评估,后期阶段及中止的计划等相关资讯。

简介

  • 调查范围

丛发性头痛;概要

治疗药的开发

  • 开发中产品;概要
  • 企业开发中的产品
  • 企业开发中的治疗药

治疗药的评估

  • 标的别
  • 各作用机制
  • 各给药途径
  • 各分子类型

开发治疗药的企业

  • Eli Lilly and Company
  • Entheogen Corp
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd
  • TrioxBio Inc

药物简介

  • BOL-148
  • fremanezumab
  • galcanezumab
  • MTR-108
  • pasireotide
  • zucapsaicin

暂停中的计划

附录

图表

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GMDHC11048IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cluster Headache Syndrome - Pipeline Review, H1 2019, provides an overview of the Cluster Headache Syndrome (Central Nervous System) pipeline landscape.

Cluster headache is pain that occurs along one side of the head. It is frequently occurs around, behind, or above the eye. Symptoms include burning, sharp, steady pain, red eye, runny nose, excessive tearing and flushed face. Risk factors include age and gender. Treatment includes anti-inflammatory (steroid) medicines and triptans.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cluster Headache Syndrome - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Cluster Headache Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cluster Headache Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cluster Headache Syndrome (Cluster Headache) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 1 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Cluster Headache Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cluster Headache Syndrome (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Cluster Headache Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cluster Headache Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cluster Headache Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cluster Headache Syndrome (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cluster Headache Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cluster Headache Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cluster Headache Syndrome (Cluster Headache) - Overview
  • Cluster Headache Syndrome (Cluster Headache) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Cluster Headache Syndrome (Cluster Headache) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cluster Headache Syndrome (Cluster Headache) - Companies Involved in Therapeutics Development
    • Clexio Biosciences Ltd
    • Crossject SA
    • Eli Lilly and Co
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd
    • TrioxBio Inc
  • Cluster Headache Syndrome (Cluster Headache) - Drug Profiles
    • CLE-500 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fremanezumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • galcanezumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MTR-108 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pasireotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • psilocybin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sumatriptan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • zucapsaicin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cluster Headache Syndrome (Cluster Headache) - Dormant Projects
  • Cluster Headache Syndrome (Cluster Headache) - Product Development Milestones
    • Featured News & Press Releases
      • Nov 14, 2018: Emgality receives Breakthrough Therapy Designation for prevention of Episodic Cluster Headache
      • Jun 15, 2018: Teva Provides Update on Clinical Trial of Fremanezumab for Use in Chronic Cluster Headache
      • May 15, 2018: Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache
      • Apr 17, 2018: Teva to Present New Data on Fremanezumab at 70th Annual Meeting of the American Academy of Neurology
      • Sep 06, 2017: Lilly To Present New Data For Galcanezumab At The 18th Congress Of The International Headache Society
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Cluster Headache Syndrome (Cluster Headache), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Cluster Headache Syndrome (Cluster Headache) - Pipeline by Clexio Biosciences Ltd, H1 2019
  • Cluster Headache Syndrome (Cluster Headache) - Pipeline by Crossject SA, H1 2019
  • Cluster Headache Syndrome (Cluster Headache) - Pipeline by Eli Lilly and Co, H1 2019
  • Cluster Headache Syndrome (Cluster Headache) - Pipeline by Novartis AG, H1 2019
  • Cluster Headache Syndrome (Cluster Headache) - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2019
  • Cluster Headache Syndrome (Cluster Headache) - Pipeline by TrioxBio Inc, H1 2019
  • Cluster Headache Syndrome (Cluster Headache) - Dormant Projects, H1 2019

List of Figures

  • Number of Products under Development for Cluster Headache Syndrome (Cluster Headache), H1 2019 7
  • Number of Products under Development by Companies, H1 2019 8
  • Number of Products by Targets, H1 2019 13
  • Number of Products by Stage and Targets, H1 2019 13
  • Number of Products by Mechanism of Actions, H1 2019 15
  • Number of Products by Stage and Mechanism of Actions, H1 2019 15
  • Number of Products by Routes of Administration, H1 2019 17
  • Number of Products by Stage and Routes of Administration, H1 2019 17
  • Number of Products by Molecule Types, H1 2019 19
  • Number of Products by Stage and Molecule Types, H1 2019 19
Back to Top